title: Sepsis and pharmacogenomics: can the VAS(S)T majority of vasopressor treatment be individualized?*.
authors.affiliation: Department of Anesthesiology, Pain Medicine and Intensive Care, University of Muenster, Muenster, Germany Department of Intensive Care Medicine, The Canberra Hospital, Australian National University, Canberra, Australia.
authors.forename: Martin
authors.initials: M
authors.lastname: Westphal
authors.forename: Frank M P
authors.initials: FM
authors.lastname: van Haren
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000009:adverse effects*; D020641:Polymorphism, Single Nucleotide; D017483:Receptors, Vasopressin / Q000235:genetics*; D012772:Shock, Septic / Q000188:drug therapy* / Q000401:mortality*; D014662:Vasoconstrictor Agents / Q000009:adverse effects*; D014667:Vasopressins / Q000009:adverse effects*
chemical_list: C000588833:AVPR1b protein, human; D017483:Receptors, Vasopressin; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D009638:Norepinephrine